Have a feature idea you'd love to see implemented?
Let us know!
KYMR Kymera Therapeutics Inc
Price (delayed)
$48.375
Market cap
$2.99B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.42
Enterprise value
$3B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
KYMR's revenue has soared by 71% YoY and by 12% from the previous quarter
KYMR's gross profit has surged by 71% year-on-year and by 12% since the previous quarter
The equity has soared by 57% YoY but it has contracted by 3.7% from the previous quarter
Kymera Therapeutics's quick ratio has increased by 21% YoY but it has decreased by 12% QoQ
KYMR's debt is up by 17% year-on-year
KYMR's net income is down by 2.1% since the previous quarter
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
61.75M
Market cap
$2.99B
Enterprise value
$3B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.33
Price to sales (P/S)
39.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.9
Revenue
$88.55M
EBIT
-$157.63M
EBITDA
-$152.45M
Free cash flow
-$137.92M
Per share
Balance sheet
Liquidity
EPS
-$2.42
Free cash flow per share
-$1.89
Book value per share
$11.16
Revenue per share
$1.21
TBVPS
$11.31
Total assets
$826.02M
Total liabilities
$141.1M
Debt
$88.18M
Equity
$684.92M
Working capital
$463.26M
Debt to equity
0.13
Current ratio
8.45
Quick ratio
8.3
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-172.2%
Gross margin
100%
Net margin
-178.3%
Operating margin
-209.6%
Return on assets
-22.4%
Return on equity
-28.9%
Return on invested capital
-25%
Return on capital employed
-20.6%
Return on sales
-178%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
-0.24%
1 week
-0.79%
1 month
2.21%
1 year
331.15%
YTD
90%
QTD
2.21%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$88.55M
Gross profit
$88.55M
Operating income
-$185.58M
Net income
-$157.85M
Gross margin
100%
Net margin
-178.3%
KYMR's revenue has soared by 71% YoY and by 12% from the previous quarter
KYMR's gross profit has surged by 71% year-on-year and by 12% since the previous quarter
KYMR's net margin is up by 42% year-on-year and by 8% since the previous quarter
The operating margin has grown by 37% YoY and by 7% from the previous quarter
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
4.33
P/S
39.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.9
The company's EPS rose by 12% YoY and by 3.6% QoQ
The equity has soared by 57% YoY but it has contracted by 3.7% from the previous quarter
The stock's price to book (P/B) is 50% more than its last 4 quarters average of 2.9 but 6% less than its 5-year quarterly average of 4.6
KYMR's revenue has soared by 71% YoY and by 12% from the previous quarter
The price to sales (P/S) is 65% higher than the last 4 quarters average of 24.2 and 33% higher than the 5-year quarterly average of 30.0
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales rose by 42% YoY and by 8% QoQ
The return on invested capital has grown by 21% year-on-year and by 7% since the previous quarter
KYMR's return on assets is up by 14% year-on-year and by 7% since the previous quarter
The company's return on equity rose by 13% YoY and by 9% QoQ
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total assets has grown by 42% YoY but it has contracted by 4.9% from the previous quarter
Kymera Therapeutics's quick ratio has increased by 21% YoY but it has decreased by 12% QoQ
KYMR's debt is 87% smaller than its equity
The equity has soared by 57% YoY but it has contracted by 3.7% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 24% YoY but it has increased by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.